Avalyn Pharma: Morgan Stanley Sees 84% Price Potential - Study Results in H2 2027 Could Significantly Minimize Remaining Risks of a Potential Multi-Blockbuster Opportunity

Fresh Wind from Successful IPO and Pipeline Progress The IPO of Avalyn Pharma (AVLN) in May 2026 has brought gross proceeds of approximately $345 million to the clinical-stage biopharma company, immediately attracting the interest of Wall Street. Since its debut on NASDAQ under ticker AVLN, the stock has been gaining increasing attention, which is supported by promising news from the research pipeline. Recent presentations by the company, including at the professional conferences of the American Thoracic Society and the European Alliance of Associations...